Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$27.1 million.

  • Kymera Therapeutics' Cash from Operations rose 4598.53% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.9 million, marking a year-over-year decrease of 8282.21%. This contributed to the annual value of -$194.5 million for FY2024, which is 8915.55% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Cash from Operations of -$27.1 million as of Q3 2025, which was up 4598.53% from -$59.9 million recorded in Q2 2025.
  • Kymera Therapeutics' Cash from Operations' 5-year high stood at $8.0 million during Q4 2023, with a 5-year trough of -$79.1 million in Q1 2025.
  • In the last 5 years, Kymera Therapeutics' Cash from Operations had a median value of -$39.0 million in 2022 and averaged -$39.2 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Cash from Operations soared by 12034.85% in 2023, and later tumbled by 86798.01% in 2024.
  • Kymera Therapeutics' Cash from Operations (Quarter) stood at -$38.4 million in 2021, then dropped by 3.09% to -$39.5 million in 2022, then soared by 120.35% to $8.0 million in 2023, then crashed by 867.98% to -$61.8 million in 2024, then skyrocketed by 56.12% to -$27.1 million in 2025.
  • Its Cash from Operations was -$27.1 million in Q3 2025, compared to -$59.9 million in Q2 2025 and -$79.1 million in Q1 2025.